Reich K, Kristensen LE, Smith SD, et al. Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial. Dermatol Pract Concept. 2022;12(2):e2022104. doi:10.5826/dpc.1202a104